Harrow, Inc. · NASDAQ:HROW
Harrow — Imprimis Pharmaceuticals — Investor Presentation (January 2015)
31 slides from Harrow's investor presentation, Jan 12, 2015
Slide 1: Imprimis Pharmaceuticals
IMPRIMIS PHARMACEUTICALS NASDAQ: IMMY MARK L. BAUM, CEO JANUARY 2015
Slide 2: Safe Harbor
imprimis SAFE HARBOR This presentation contains express "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlyi
Slide 3: Introduction
INTRODUCTION
Slide 4: Elephant in the Room
imprimis ELEPHANT IN THE ROOM Of 220 drugs approved over the past decade for publicly traded companies, the companies that invented 3 or more medicines spent an average $4.3 billion in R&D per drug. September 2013 “Eroom’s law — that's Moore’s law backward — observes that the number of new drugs app
Slide 5: Vision
Slide 6: Introduction
INTRODUCTION We sell high quality compounded drugs made by and distributed from Imprimis-owned pharmacies We focus on proprietary formulations, but we also sell related higher margin non-proprietary products We are focused in ophthalmology and urology Our disruptive ophthalmology brands and formulat
Slide 7: Ophthalmology Business
OPHTHALMOLOGY BUSINESS - DROPLESS THERAPY™ - LESSDROPS™
Slide 8: Ocular Surgery Market
imprimis OCULAR SURGERY MARKET In Need of a Solution » Standard of care for most procedures is self-administered steroid, NSAID and antibiotic eye drop therapy » $1B+ is spent on eye drops in the US alone » Eye drops create significant patient compliance issues; high costs to patients; and increased
Slide 9: Imprimis Core Technology
Imprimis CORE TECHNOLOGY , Our solubilizing [= technology allows active drugs to mix J yA and become usable ( as an injection oras a Tiameinolone Ace combination eye drop \oxifloxacin HC! Fancinoione-IWIOX (15/1)mgimL Steri#? Without our technology, large, irregular un-usable clumps of active drugs
Slide 10: Dropless Therapy
imprimis DROPLESS THERAPY™ * Our Tri-Moxi and Tri-Moxi-Vanc patent-pending compounded antibiotic and steroid formulations are available in single, injectable intraocular doses for administration during ocular surgery, primarily cataract surgery * Dropless Therapy™ benefits include: * Simplifying the
Slide 11: Cataract Patient Profile: Drop Therapy
Imprimis Cataract Patient Profile 80 years old Arthritic hands + Scoliosis Lives alone + Fixed income 2 Weeks Post-Operative Difficulty administering drops Confusion on drop regimen Runs out and no refills available Patient Surgery Scheduled MD writes prescriptions for topical non-steroidal, anti- i
Slide 12: Cataract Patient Profile: Patient Journey with Dropless
imprimis GO Cataract Patient Profile 80 years old Arthritic hands + Scoliosis Lives alone + Fixed income 4 Week Post-Operative Eye looks quiet No infection No inflammation DROP LESS? Surgery Scheduled No pre- or post- operative drops prescribed Informed about Dropless Therapy 4 Month Post-Operative
Slide 13: Go Dropless Campaign
Imprimi: GO DROPLESS™ CAMPAIGN Since the launch of our Go Dropless campaign in April 2014: Dropless Therapy™ available in 38 states 50,000+ Dropless surgeries >200 prescribing MDs and growing weekly Opportunities outside US for Dropless Therapy™ Over 40 trade media references Dropless published in 2
Slide 14: Potential Benefit to Medicare
POTENTIAL BENEFIT TO MEDICARE Of the 3.6M Cataract Procedures in the US Annually, ~2.8 Million are for Medicare Recipients Potential Dropless Therapy™ Savings = $960 Million/Yr. COST PER THERAPY TOTAL COST = Drop Therapy mDropless Therapy* *Dropless Therapy Total Cost assumes 5% of patients may need
Slide 15: LessDrops Platform
imprimis LESSDROPS™ PLATFORM Tri-Moxi and Pred-Moxi Combination Eye Drops* * Additional proprietary combinations planned for 2015 = Lower Cost: Proprietary Tri-Moxi and Pred-Moxi combination eye drop formulations may cost up to 75% less than current eye drop treatment regimens = Better Compliance: E
Slide 16: Ocular Surgery Market
OCULAR SURGERY MARKET LASIK AND REFRACTIVE SURGERY = Over half of Americans require some form of vision correction = Estimated 43M are candidates for refractive surgery = More than 35M LASIK procedures have been performed worldwide since approval in 1999 = Over 700,000 LASIK procedures are performed
Slide 17: 2015 Investigator Studies
imprimis 2015 INVESTIGATOR STUDIES Prospective NJ 60 eyes To evaluate endothelial cell count in patients who receive randomized [+I study, triamcinolone 15mgiml, moxifloxacin 1mg/ml, and single site (IND) vancomycin 10mg/ml compounded ophthalmic injection versus triamcinolone and moxifloxacin Prospe
Slide 18: Urology Business
UROLOGY BUSINESS - HEP-LIDO-A (DEFEAT IC™) - PENTOXIFYLLINE (PEYRONIE’S)
Slide 19: About Interstitial Cystitis
imprimis ABOUT INTERSTITIAL CYSTITIS * Estimated 10M US men and women suffer from interstitial cystitis (IC), commonly referred to as painful bladder syndrome (PBS) * Chronic disease characterized by mild to severe bladder pressure and pain, pelvic pain and pain after sexual intercourse * Frequent u
Slide 20: Patented IC/PBS Formulation
impri PATENTED IC/PBS FORMULATION Urothetium Blood vessels Glomerulations » We own the rights to a patented alkalized heparin and lidocaine formulation (Hep-Lido-A) developed by Lowell Parsons, MD, inventor of Elmiron®, the only FDA-approved drug to treat IC/PBS * Studies have shown that instillatio
Slide 21: Injectable Pentoxifylline
imprimis INJECTABLE PENTOXIFYLLINE * Our patent-pending injectable pentoxifylline formulation for the treatment of Peyronie’s disease (PD) is being studied by a leading group of urologists, with results of this research expected in 2015 * PD is the development of fibrous scar tissue inside the penis
Slide 22: Pharmacy Business
PHARMACY BUSINESS - IMPRIMISRx™
Slide 23: ImprimisRx Business
imprimis ImprimisRx™ Business Imprimis’ PCAB®-Accredited Pharmacies rwi . PHARMACY Amie § CREATICNS Park Compounding, Irvine, CA Pharmacy Creations, Randolph, NJ Acquired January 1, 2015 Acquired April 1, 2014 (Est. 2014 revenues nearly $4M) = All Rx orders for Imprimis formulations are dispensed at
Slide 24: Conclusion
imprimis CONCLUSION Unique capital efficient business model Valuable intellectual property * Rapidly growing Dropless Therapy™ and LessDrops™ ophthalmology franchises * Urology business poised to accelerate growth « Pharmacy infrastructure in place to support growth in 2015 and beyond
Slide 25: Company Profile
COMPANY PROFILE Trading Symbol: NASDAQ: IMMY Current Price per Share (1-9-15): $7.90 Market Cap: $73 Million 52-Wk Range: $4.24 - $9.62 Average Daily Trading Volume: 15,000 shares Number of Employees: 62 Headquarters: San Diego, CA 503A Pharmacies: Randolph, NJ and Irvine, CA Financial Info: « No pr
Slide 26: Contact Us
CONTACT US Imprimis Pharmaceuticals (NASDAQ: IMMY) “ese” | e | Iimprimi 12264 El Camino Real, #350 | PHARMACEUTICALS San Diego, CA 92130 | 858-704-4040
Slide 27: Appendix
APPENDIX
Slide 28: Dropless Clinical Presentations
imprimis DROPLESS CLINICAL PRESENTATIONS Leading ophthalmologists have conducted clinical studies and presented their findings on Dropless Therapy™ including: M. Stewart Galloway, MD » ASCRS 2014, Boston: Intravitreal Placement of Antibiotic/Steroid as a Substitute for Post-operative Drops Following
Slide 29: Training & Education
imprimis TRAINING & EDUCATION Training Portal Development and Website Relaunch Online training portal GoDropless.com 29
Slide 30: Practice Marketing
PRACTICE MARKETING Patient Brochures Social Media mo | / PRTemplote Digital Assets — Direct Mailers * Promotions for physicians to gain a competitive advantage + Locator map at www.GoDropless.com with physician locations * Physician marketing toolkit to spread patient awareness 30
Slide 31: Quality Is Paramount
imprimis QUALITY IS PARAMOUNT USP <797> PCAB imprimisRx Status STERILITY TESTING. Stosle bts per USP <71> ‘Comply with USP. v ENDOTOXIN TESTING | Stetile Injectable kts per USP <85> ‘Comply with USP. A PRE-SHIPMENT ert Nol required, but recommended ‘Comply with USP. v ENVIRONMENTAL een Every 6 mons
Imprimis Pharmaceuticals — Investor Presentation (January 2015) on 6ix